Welcome to our dedicated page for Eiger BioPharmaceuticals news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals stock.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) is a commercial-stage biopharmaceutical company headquartered at 500 Crescent Ct Ste 300, Dallas, Texas. The company focuses on the development of innovative therapies for rare and ultra-rare diseases.
Recently, Eiger has redirected its efforts towards the development of avexitide for hyperinsulinemic hypoglycemia indications. This includes significant potential in treating post-bariatric hypoglycemia (PBH), where Phase 2 clinical trials have shown promising results, and the FDA has provided alignment on Phase 3 endpoints and study design. Eiger also plans to develop avexitide for congenital hyperinsulinism as a secondary indication.
The company continues to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL). Eiger recently received marketing approval for Zokinvy in Japan through a partnership with AnGes, Inc., further expanding its global reach.
In a strategic move, Eiger is exploring partnering opportunities for its virology assets, including lonafarnib-based regimens for hepatitis delta virus (HDV) and peginterferon lambda. Despite recent challenges, such as the discontinuation of the Phase 3 LIMT-2 study of peginterferon lambda due to safety concerns, Eiger remains committed to its primary goals.
Financially, Eiger reported total revenue of $4.6 million for Q2 2023 and $3.2 million for Q3 2023, indicating a stable financial condition supported by strategic cost reductions and workforce optimization. The company’s cash runway is extended into the fourth quarter of 2024, enhancing its capacity to pursue ongoing projects and strategic initiatives.
As of January 2024, Eiger announced a 1-for-30 reverse stock split to comply with Nasdaq's listing requirements and maintain its market position. The company is also navigating a Chapter 11 bankruptcy process to facilitate an orderly wind down of its operations and the sale of its assets, including a “stalking horse” agreement for Zokinvy.
Dr. David Apelian, with extensive experience in clinical development and regulatory affairs, leads Eiger as its CEO, guiding the company through these transformative times.
For further details and updates, visit the company’s website at www.eigerbio.com.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced significant presentations at the 24th Biennial HEP DART 2021 meeting from December 5-9 in Cabo San Lucas, Mexico. Key highlights include oral presentations on late-stage HDV treatments like Lonafarnib and Peginterferon Lambda scheduled for December 9, as well as a poster on the LIMT-2 Phase 3 study. Eiger's focus is on developing innovative therapies that could potentially benefit over 12 million global HDV patients. The company has multiple therapies in Phase 3 with FDA Breakthrough Therapy Designation.
Eiger BioPharmaceuticals, a biopharmaceutical company focused on innovative therapies for Hepatitis Delta Virus (HDV) and rare diseases, will present corporate updates at two investor conferences in November 2021. David Cory, President and CEO, will speak at the Stifel 2021 Virtual Healthcare Conference on November 17 at 4:40 PM ET and at the Jefferies London Healthcare Conference on November 18 (pre-recorded). Both presentations will be webcasted, and Eiger will also conduct one-on-one investor meetings. The company has been granted FDA Breakthrough Therapy Designation for its HDV therapies.
Eiger BioPharmaceuticals reported Q3 2021 financial results showing net revenues of $3.0 million from Zokinvy sales, up from $2.1 million in Q2 2021. The company incurred a net loss of $22.2 million, or $0.65 per share. R&D expenses jumped to $18.1 million, primarily due to clinical trials, while total operating expenses included $3.0 million in non-cash expenses. Cash and investments at the end of Q3 totaled $120.4 million, expected to fund operations into Q4 2023. The company is advancing multiple Phase 3 studies for HDV treatments and has a positive outlook for Zokinvy sales.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announces a virtual Key Opinion Leader (KOL) event on November 15, 2021, from 9:00-10:30 AM ET, focusing on Hepatitis Delta Virus (HDV) infection. The event will feature discussions on HDV disease and potential treatments, including Eiger's therapies: Lonafarnib and Peginterferon Lambda. Leading experts such as Dr. Pietro Lampertico, Dr. Norah Terrault, and Dr. Ohad Etzion will present insights. Attendees can join via phone or webcast through Eiger's website, with an archive available for 90 days.
Eiger BioPharmaceuticals announced the completion of enrollment in the Phase 3 D-LIVR study, which examines Lonafarnib for chronic hepatitis delta virus (HDV) infection. This trial, the largest of its kind with 400+ patients across 116 sites in 22 countries, aims to compare two treatment regimens against a placebo. The results are crucial for potential U.S. and European approvals. Topline data is expected by the end of 2022, marking a significant milestone for Eiger and offering hope for improved treatment options for HDV patients.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) announced a conference call for November 4, 2021, at 4:30 PM ET to discuss its third-quarter financial results and provide a business update. The company specializes in developing targeted therapies for rare diseases, particularly focusing on Hepatitis Delta Virus (HDV) with treatments including Lonafarnib and peginterferon lambda, both in Phase 3 studies. Interested parties can access the live call via phone or through a webcast on Eiger's website.
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced the appointment of Erik Atkisson as General Counsel and Chief Compliance Officer. As part of this, he received a stock option grant for 180,000 shares with an exercise price of $6.68, the closing price on September 30, 2021. The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is aimed at inducing Mr. Atkisson to join the company.
Eiger BioPharmaceuticals has appointed Erik Atkisson as General Counsel and Chief Compliance Officer. With over twenty years of experience, Atkisson's previous roles include Chief Compliance Officer at Cytokinetics and Deputy General Counsel at Nevro. This leadership change is expected to enhance the company's governance and compliance as it advances its late-stage pipeline with five Breakthrough Therapy Designations. Eiger focuses on therapies for serious rare diseases, including Hepatitis Delta Virus and Hutchinson-Gilford Progeria Syndrome.
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced that the Data Safety Monitoring Board (DSMB) has recommended continuing enrollment for the Peginterferon Lambda arm in the Phase 3 TOGETHER study, evaluating treatments for high-risk, non-hospitalized COVID-19 patients. The interim analysis was based on data from 453 patients. The study aims to recruit up to 800 patients and assesses clinical outcomes in emergency visits and hospitalizations. Eiger's Peginterferon Lambda may effectively treat COVID-19, targeting immune responses critical against virus variants.
Eiger BioPharmaceuticals (Nasdaq: EIGR) is set to participate in two key investor conferences in September 2021. The events include the Citi's 16th Annual BioPharma Virtual Conference on September 9 where CEO David Cory will discuss drug development for rare diseases, and Baird's 2021 Global Healthcare Conference on September 15 for a corporate update. Eiger will also offer one-on-one meetings with investors at both conferences. A live webcast of the Citi panel will be available on their website.
FAQ
What is the market cap of Eiger BioPharmaceuticals (EIGR)?
What is Eiger BioPharmaceuticals' focus?
What are Eiger's lead products?
What recent strategic changes has Eiger made?
How is Eiger financially performing?
Who is leading Eiger BioPharmaceuticals?
What is the significance of the reverse stock split?
What is avexitide used for?
What is Zokinvy® (lonafarnib)?
What is the status of Eiger's virology assets?
Where can I find more information about Eiger?
